Study of Atenolol Influence on Blood Pressure During Resistance Exercise

NCT ID: NCT01030016

Last Updated: 2009-12-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-05-31

Study Completion Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study was designed to investigate if atenolol is able to blunt blood pressure increase during resistance exercise in hypertensive subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study compared intra-arterial blood pressure responses during leg-extension resistance exercise performed to fatigue at 40, 80 and 100% of 1 RM in hypertensive patients receiving placebo (first) and atenolol (second) on a single blind manner.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blood Pressure Exercise

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

resistance exercise beta-blockers blood pressure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

atenolol

subjects received 6 weeks of atenolol

Group Type EXPERIMENTAL

atenolol

Intervention Type DRUG

25 mg/day, twice a day for 6 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

atenolol

25 mg/day, twice a day for 6 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

beta-blockers

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* hypertension with blood pressure levels below 160/105 mmHg under placebo.
* age between 30 and 60 years
* nonobese

Exclusion Criteria

* target organ lesion
* cardiovascular risk factor
* cardiovascular disease
* physically active
Minimum Eligible Age

30 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

Sponsor Role collaborator

University of Sao Paulo

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

School of Physical Education and Sport, University of São Paulo

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cláudia LM Forjaz, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Sao Paulo

Decio Mion Jr, PhD

Role: STUDY_CHAIR

University of Sao Paulo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of São Paulo

São Paulo, São Paulo, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FAPESP-06/06356-8

Identifier Type: -

Identifier Source: org_study_id